Atossa Therapeutics(ATOS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual Meeting • Completed enrollment in 80mg PK Run-in Cohort for EVANGELINE trial • Completed Phase 2 Karisma-Endoxifen clinical trial dosing • Updated protocol for (Z)-Endoxifen and abemaciclib clinical tri ...